Literature DB >> 15956162

Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Michael A Hauser1, Yi-Ju Li, Hong Xu, Maher A Noureddine, Yujun S Shao, Steven R Gullans, Clemens R Scherzer, Roderick V Jensen, Adam C McLaurin, Jason R Gibson, Burton L Scott, Rita M Jewett, Judith E Stenger, Donald E Schmechel, Christine M Hulette, Jeffery M Vance.   

Abstract

BACKGROUND: Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Genes contributing to rare mendelian forms of PD have been identified, but the genes involved in the more common idiopathic PD are not well understood.
OBJECTIVES: To identify genes important to PD pathogenesis using microarrays and to investigate their potential to aid in diagnosing parkinsonism.
DESIGN: Microarray expression analysis of postmortem substantia nigra tissue. PATIENTS: Substantia nigra samples from 14 unrelated individuals were analyzed, including 6 with PD, 2 with progressive supranuclear palsy, 1 with frontotemporal dementia with parkinsonism, and 5 control subjects. MAIN OUTCOME MEASURES: Identification of genes significantly differentially expressed (P<.05) using Affymetrix U133A microarrays.
RESULTS: There were 142 genes that were significantly differentially expressed between PD cases and controls and 96 genes that were significantly differentially expressed between the combined progressive supranuclear palsy and frontotemporal dementia with parkinsonism cases and controls. The 12 genes common to all 3 disorders may be related to secondary effects. Hierarchical cluster analysis after exclusion of these 12 genes differentiated 4 of the 6 PD cases from progressive supranuclear palsy and frontotemporal dementia with parkinsonism.
CONCLUSIONS: Four main molecular pathways are altered in PD substantia nigra: chaperones, ubiquitination, vesicle trafficking, and nuclear-encoded mitochondrial genes. These results correlate well with expression analyses performed in several PD animal models. Expression analyses have promising potential to aid in postmortem diagnostic evaluation of parkinsonism.

Entities:  

Mesh:

Year:  2005        PMID: 15956162     DOI: 10.1001/archneur.62.6.917

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  67 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

Review 2.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 3.  Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons.

Authors:  F M J Jacobs; S M Smits; K J M Hornman; J P H Burbach; M P Smidt
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

Review 4.  Microarrays in Parkinson's disease: a systematic approach.

Authors:  Renee M Miller; Howard J Federoff
Journal:  NeuroRx       Date:  2006-07

Review 5.  Finding diamonds in the rubble.

Authors:  Jang-Ho J Cha
Journal:  Exp Neurol       Date:  2007-02-20       Impact factor: 5.330

6.  Heat shock protein responses to aging and proteotoxicity in the olfactory bulb.

Authors:  Tyler S Crum; Amanda M Gleixner; Jessica M Posimo; Daniel M Mason; Matthew T Broeren; Scott D Heinemann; Peter Wipf; Jeffrey L Brodsky; Rehana K Leak
Journal:  J Neurochem       Date:  2015-03-05       Impact factor: 5.372

7.  Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip.

Authors:  Cintia Roodveldt; Carlos W Bertoncini; August Andersson; Annemieke T van der Goot; Shang-Te Hsu; Rafael Fernández-Montesinos; Jannie de Jong; Tjakko J van Ham; Ellen A Nollen; David Pozo; John Christodoulou; Christopher M Dobson
Journal:  EMBO J       Date:  2009-10-29       Impact factor: 11.598

8.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

9.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

10.  A cross-study transcriptional analysis of Parkinson's disease.

Authors:  Greg T Sutherland; Nicholas A Matigian; Alistair M Chalk; Matthew J Anderson; Peter A Silburn; Alan Mackay-Sim; Christine A Wells; George D Mellick
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.